This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Aeterna (AEZS) This Earnings Season?
by Zacks Equity Research
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
by Zacks Equity Research
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
by Zacks Equity Research
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
by Zacks Equity Research
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
by Zacks Equity Research
Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.
5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
by Zacks Equity Research
Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
Top Stock Reports for Sanofi, Novo Nordisk & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Sanofi (SNY), Novo Nordisk (NVO) and NVIDIA (NVDA).
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.
PFE vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk (NVO) Faces Pricing Pressure and Competition
by Zacks Equity Research
Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Lilly's Novel Diabetes Candidate Shows Promise in Phase II
by Zacks Equity Research
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.